Get CME Credits

Creators:

PeerView & the DTRF (Made possible with support from SpringWorks Therapeutics)

Availability:

Now through December 29, 2023

Access Program

Mediums:

The PeerView onDemand presentation can be downloaded in MP3 format, and the entire program is available as a podcast via the PeerView channels on Apple Podcasts, Spotify, TuneIn, Google Podcasts, and Amazon Alexa. The podcasts and online media player are fully compatible with all mobile devices. Furthermore, all the slides are easily downloadable as a PowerPoint slide kit.

Description:

The treatment and management for desmoid tumors is currently transitioning from surgical approaches to more conservative strategies by utilizing systemic therapies. Systemic therapies travel through blood to cells all over the body, to the whole “system.” The discovery that desmoid tumors are universally associated with genetic alterations in the Wnt/β-catenin pathway led to the development of gamma secretase inhibitors (GSIs). GSIs are a new promising class of therapies, and several are in late-phase testing.

This PeerView educational activity, was based on a the CTOS 2022 Live Hybrid Symposium held on November 29, 2022 with the replay immediately following. This on-demand activity is available for CME credit through December 29, 2023 and features a panel of leading experts in managing patients with desmoid tumors. They provide expert insights and practical guidance for navigating the latest treatment advances, including GSIs for desmoid tumors. In addition, they discuss illustrative cases and clinical scenarios to demonstrate the emerging role and integration of novel GSIs in real-world patient care settings.

This learner interactive PeerView program is chaired and presented by Bernd Kasper, MD, PhD from the Mannheim Cancer Center (MCC) in Mannheim, Germany. Dr. Kasper is joined on the faculty by Mrinal Gounder, MD from the Memorial Sloan Kettering Cancer Center in New York, New York and Alessandro Gronchi, MD from the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.

Upon completion of this activity, participants should be better able to:

• Describe the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of adult and pediatric desmoid tumors
• Implement validated strategies that harness multidisciplinary team-based approaches to diagnose desmoid tumors, including referring patients to sarcoma specialists
• Integrate novel therapeutic approaches based on current evidence to include emerging therapies in the context of clinical trial enrollment into the treatment plans of patients with desmoid tumors

Creators:

PeerView Institute for Medical Education (PVI) & the Desmoid Tumor Research Foundation (DTRF) (Made Possible with support from SpringWorks Therapeutics)

Availability:

Now through February 22, 2024.

Access Program

Description:

Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors.

This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions.

This PeerView program is chaired and presented by Ravin Ratan, MD, M.Ed from the MD Anderson Cancer Center. Dr. Ratan is joined on the faculty by Christina L. Roland, MD, MS, FACS, from MD Anderson Cancer Center and desmoid tumor patient, Kathleen Hodgkins.

Upon completion of this activity, participants should be better able to:

• Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors
• Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors
• Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences